Biotech Values

[biomaven0]

Botox decreases CGRP levels between attacks in chronic migraine patients:

Abstract
Pain. 2015 Feb 12. [Epub ahead of print]
OnabotulinumtoxinA decreases interictal CGRP plasma levels in chronic migraine patients.
Cernuda-Morollón E1, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J.
Author information
Abstract
: OnabotulinumtoxinA (onabotA) has shown efficacy in chronic migraine (CM). Its mechanism of action, however, remains obscure. We have analysed whether treatment with onabotA is able to induce changes in interictal plasma calcitonin generelated peptide (CGRP) concentrations, which have been shown to be increased in CM patients. CGRP levels were determined in samples obtained from the right antecubital vein by ELISA, outside a migraine attack and having taken no symptomatic medication in the previous 24 h, in 83 CM patients (average age 44 years; 94% females) before and one month after treatment with 155-195 U of onabotA. CGRP levels after onabotA treatment (median 51.89 pg/ml; range 199.4-10.2) were significantly decreased as compared to CGRP levels obtained before onabotA treatment (median 74.09 pg/ml; range 241.0-11.4; p=0.001). Pretreatment CGRP levels in responders (76.85 pg/ml) were significantly higher than those seen in nonresponders (50.45 pg/ml; p=0.001). One month after treatment, CGRP levels did not change in nonresponders (51.89 pg/ml; p=NS), but significantly decreased in responders (52.48 pg/ml; p= 0.003). A number of demographic factors, clinical features and comorbidities were not different in responders as compared to nonresponders. These results confirm that interictal CGRP levels can be of help on predicting the response to onabotA and suggest that the mechanism of action onabotA in CM is the reversal of sensitization as a result of the inhibition of CGRP release.

http://www.ncbi.nlm.nih.gov/pubmed/25735000

Supportive of the companies targeting CGRP.